Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Randomized Trial of Amcenestrant vs Physician’s Choice Endocrine Monotherapy in ER-positive, HER2-negative Advanced Breast Cancer
jRCT2080224980Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2019
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of amcenestrant in breast cancer (2 arms), sponsored by Sanofi. Primary endpoint: Progression-free survival. Started Dec 2019; status: completed.
02
Drugs
amcenestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080224980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224980.